Skip to main content
Editas Medicine, Inc. logo

Editas Medicine, Inc. — Investor Relations & Filings

Ticker · EDIT ISIN · US28106W1036 LEI · 5299000AON4Q9NT2JE42 US Professional, scientific and technical activities
Open in API
Filings indexed 679 across all filing types
Latest filing 2019-02-07 Board/Management Inform…
Country US United States of America
Listing US EDIT

About Editas Medicine, Inc.

https://www.editasmedicine.com/

Editas Medicine, Inc. is a clinical-stage genome editing company focused on developing transformative medicines for serious diseases using CRISPR technology. The company's mission is to discover, develop, and commercialize durable, precision genomic therapies that can correct the underlying genetic causes of various conditions. Its proprietary platform enables the precise revision, removal, or replacement of DNA. Editas Medicine's research and development pipeline is concentrated on creating both in vivo (in-body) and ex vivo (out-of-body) gene-edited medicines to treat a broad class of diseases, with a focus on rare genetic disorders.

Recent filings

Filing Released Lang Actions
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated February 7, 2019, reporting on February 5, 2019 events. The content focuses on the appointment of a new director, David T. Scadden, M.D., and changes in senior management, including the appointment of an interim Chief Financial Officer and a principal executive officer. There are no financial statements or detailed financial performance data presented. The primary subject is changes in the company's board of directors and senior management. According to the filing definitions, announcements of changes in the company's board or senior management fall under Board/Management Information (MANG). The document length (8317 characters) is sufficient to contain substantive information, not just a brief announcement. Therefore, the appropriate classification is MANG with high confidence.
2019-02-07 English
FORM 4 -
Director's Dealing
2019-02-06 English
FORM 4 -
Director's Dealing
2019-02-04 English
FORM 4 -
Director's Dealing
2019-02-04 English
FORM 4 -
Director's Dealing
2019-02-04 English
Major Shareholding Notification 2019
Major Shareholding Notification
2019-02-04 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.